Towards Improved Immunotherapy
Clinical Immunology publishes novel approach that can augment clinical outcomes
Amsterdam, December 1, 2008 – A study published by Elsevier this month in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method that facilitates the induction of a specific type of immune suppressive cells, called ‘regulatory T cells’ for therapeutic use. These immune suppressive cells show great potential for the treatment of autoimmune diseases and improving transplantation outcomes.
Immunotherapy refers to a collection of treatments based upon the concept of modulating the immune system to achieve a prophylactic and/or therapeutic goal. For example, inducing immune suppression could dampen an abnormal immune response in autoimmune diseases or could reduce a normal immune response to prevent rejection of transplanted organs or cells. Regulatory T cells are an important part of the immune system and can play a suppressive role, but naturally occur in low numbers.
Michael Albert and colleagues from the Ludwig-Maximilians-University in Munich, Germany, describe a unique strategy that facilitates the induction of regulatory T cells ex vivo with subsequent expansion to numbers adequate for immunotherapy. Using an inexpensive, fast and simple high-yield method they generated regulatory T cells from small amounts of peripheral blood which, potentially, could be transferred back into a patient enabling a clinically desired immune suppression.
“Feasible protocols to provide large amounts of regulatory T cells are in great demand”, said Andy Saxon”, the Editor-in-Chief of Clinical Immunology, “this article describes a relative simple but exciting method which can be used in clinical settings such as transplantation”.
Notes to editors:
M.H. Albert, X-Z. Yu, T. Magg, Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells, 2008 Clinical Immunology, 129(3): 381-393.
The Clinical Immunology Society (CIS) is an international professional organization which includes more than 750 clinicians, investigators and trainees. The mission of the CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic / inflammatory disorders.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a world-leading provider of information and analytics to professionals and business customers, in a wide range of industries. www.elsevier.com
Floris de Hon
+31 20 485 2498